Skip to main content

3D-QSAR Study of Flavone Derivatives as Inhibitors of HeLa Cervix Adenocarcinoma Cell Lines

Buy Article:

$68.00 + tax (Refund Policy)

During the last century, flavonoids have been identified as multifunctional compounds with properties and biological activities that depend on their diverse functional groups, which may include hydroxyl, methyl, methoxy, glycosyl, isoprenyl, and various polymeric groups. In particular, methoxy groups located on the basic flavonoid structure are intimately interrelated to bioavailability and translocation in cells. The relationships between structure and activity of 23 flavones, including a methoxylated flavone, were evaluated with regard to their cytotoxic effects in cervical cancer cells. Comparative molecular field analyses (CoMFA) and comparative molecular similarity index analyses (CoMSIA) were performed to improve predictive 3D-QSAR models. Models generated from CoMFA and CoMSIA yielded cross-validated correlation coefficient values (q2) of 0.602 and 0.537, and non-cross-validated values (r2) of 0.964 and 0.965, respectively. Thus, this study provides valuable information on the suitability of modified flavones as chemotherapeutic agents. In addition, CoMFA and CoMSIA contour maps were used to design and structurally modify a flavone compound with functional groups to maximize its anticancer effects.

Keywords: Adenocarcinoma; CoMFA; CoMSIA; biophore; cytotoxicity; flavonoid-derivatives

Document Type: Research Article

Publication date: 01 August 2015

More about this publication?
  • Letters in Drug Design & Discovery publishes original letters on all areas of rational drug design and discovery including medicinal chemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, and structure-activity relationships. The emphasis will be on publishing quality papers very rapidly. Letters will be processed rapidly by taking full advantage of Internet technology for both the submission and review of manuscripts. The journal is essential reading to all pharmaceutical scientists involved in research in drug design and discovery.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content